Opinion

Video

Treatment Considerations and Role of Trimodal Therapy in Bladder Cancer

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

Expert perspectives on treatment options available for patients with bladder cancer and the role of trimodal therapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Related Videos
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Félix Guerrero-Ramos, MD, on TAR-200 in papillary disease-only NMIBC
      Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
      Joshua J. Meeks, MD, PhD, discusses NIAGARA data for patient undergoing cystectomy
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Joseph Jacob, MD, on the durability of TAR-200 in NMIBC
      Study data point to gender disparities in oncology research citations
      Study data point to gender disparities in oncology research citations
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Matthew Galsky, MD, on patient selection for perioperative durvalumab/chemo in MIBC
      Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
      Suzanne B. Merrill, MD, FACS, discusses rBCG and the NMIBC landscape
      Urinary bladder | Image Credit: © magicmine - stock.adobe.com
      Expert describes implications of neoadjuvant durvalumab approval in MIBC
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      Sima Porten, MD, on gene-environment interactions in bladder cancer development
      3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
      How rBCG EAP could open up access for Anktiva in bladder cancer
      Betty Wang, MD, discusses studies from the 2025 EAU meeting
      Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
      Related Content
      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept
      May 5th 2025

      FDA issues refusal to file letter on sBLA for nogapendekin alfa inbakicept

      Hannah Clarke
      The sBLA for NAI was submitted to the FDA in March 2025.
      Dr. Schwen on focal therapies for prostate cancer
      January 11th 2024

      Dr. Schwen on focal therapies for prostate cancer

      Cleveland Clinic
      Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
      Blur image of hospital corridor | Image Credit: © whyframeshot - stock.adobe.com
      April 29th 2025

      Cxbladder Triage may help patients avoid unnecessary cystoscopies

      Benjamin P. Saylor
      The study population was able to avoid 952 cystoscopies and 71 CT scans, according to the investigators.
      medical depiction of bladder cancer
      May 31st 2023

      Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

      Urology Times staff
      In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
      Sandip M. Prasad, MD, MPhil
      April 27th 2025

      UGN-102 positions itself as an alternative to TURBT for low-grade NMIBC

      Benjamin P. Saylor
      "I would argue that UGN-102 may very well represent a well-tolerated alternative to TURBT as primary treatment for patients with low-grade disease,” says Sandip M. Prasad, MD, MPhil.
      Blur image of hospital corridor | Image Credit: © jakkapan - stock.adobe.com
      April 27th 2025

      Estimated DOR of 2 years is seen with UGN-102 in LG-IR-NMIBC

      Benjamin P. Saylor
      The investigators reported that the median Kaplan-Meier estimate of DOR was 24.2 months.
      © 2025 MJH Life Sciences

      All rights reserved.